Amgen will buy Micromet for $1.16 billion

01/26/2012 | Genetic Engineering & Biotechnology News

Amgen's acquisition of Micromet for $11 a share was approved by the boards of both companies. The cash transaction, worth about $1.16 billion, gives Amgen access to Micromet's antibody technology Bispecific T-cell Engager and its blood cancer drug candidate blinatumomab.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA